EUCTR2011-005409-65-DE
Active, not recruiting
Not Applicable
A Phase 3 Evaluation of Daclatasvir in Combination with Peginterferon Lambda-1a and Ribavirin (RBV) or Telaprevir in Combination with Peginterferon Alfa-2a and RBV in Patients with Chronic Hepatitis C Genotype 1b who are Treatment Naïve or Prior Relapsers to Alfa/RBV Therapy (The STRUCTURE Study)Revised Protocol 03, incorporating Amendment 09 (version 1.0, dated 09-Jul-2013)+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 1.0, dated 21-Jun-12) - The STRUCTURE Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Chronic Hepatitis C Virus Infection (Genotype 1b)
- Sponsor
- Bristol-Myers Squibb International Corporation
- Enrollment
- 585
- Status
- Active, not recruiting
- Last Updated
- 10 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients chronically infected with HCV GT\-1b
- •Naïve to prior treatment or documented evidence of relapse after completion of the prescribed duration of treatment (duration may be 24 or 48 weeks, to be determined based upon local guidelines)
- •HCV RNA viral load \= 100,000 IU/mL at screening
- •Patients with compensated cirrhosis are permitted
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 527
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 58
Exclusion Criteria
- •Infection with HCV other than GT\-1b
- •Positive HBsAg or HIV\-1/HIV\-2 antibody test at screening
- •Evidence of chronic liver disease caused by diseases other than chronic HCV infection
- •Current evidence of or history of variceal bleeding, hepatic encephalopathy, or ascites requiring diuretics or paracentesis or evidence of any of these findings on physical examination performed at screening
- •Current or known history of cancer (except adequately treated in situ carcinoma of the cervix, or basal or squamous cell carcinoma of the skin) within 5 years prior to screening
- •Current evidence or known history of decompensated cirrhosis based on radiologic criteria or biopsy results and clinical criteria
- •Laboratory values: hemoglobin \< 12\.0 g/dL (males) or \< 11\.0 g/dL (females), platelets \<90,000/mm³, total serum bilirubin \= 2 mg/dL (unless due to Gilbert’s disease)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Efficacy and safety evaluation of a regimen consisting of peginterferon lambda-1a + ribavirin + daclatasvir (Lambda + RBV + DCV) in HCV genotype 1b treatment naïve patients or prior relapsers to peginterferon alfa + ribavirin (alfa + RBV) therapyChronic Hepatitis C Virus Infection (Genotype 1b)MedDRA version: 16.0 Level: PT Classification code 10008912 Term: Chronic hepatitis C System Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2011-005409-65-GBBristol-Myers Squibb International Corporation641
Active, not recruiting
Not Applicable
Efficacy and safety evaluation of a regimen consisting of peginterferon lambda-1a + ribavirin + daclatasvir (Lambda + RBV + DCV) in HCV genotype 1b treatment naïve patients or prior relapsers to peginterferon alfa + ribavirin (alfa + RBV) therapyChronic Hepatitis C Virus Infection (Genotype 1b)MedDRA version: 16.1Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2011-005409-65-PLBristol-Myers Squibb International Corporation585
Active, not recruiting
Not Applicable
Efficacy and safety evaluation of a regimen consisting of peginterferon lambda-1a + ribavirin + daclatasvir (Lambda + RBV + DCV) in HCV genotype 1b treatment naïve patients or prior relapsers to peginterferon alfa + ribavirin (alfa + RBV) therapyChronic Hepatitis C Virus Infection (Genotype 1b)MedDRA version: 14.1Level: LLTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2011-005409-65-ESBristol-Myers Squibb International Corporation585
Active, not recruiting
Not Applicable
Efficacy and safety evaluation of a regimen consisting of peginterferon lambda-1a + ribavirin + daclatasvir (Lambda + RBV + DCV) in HCV genotype 1b treatment naïve patients or prior relapsers to peginterferon alfa + ribavirin (alfa + RBV) therapyEUCTR2011-005409-65-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO585
Unknown
Phase 3
A Phase 3 Evaluation of Daclatasvir in Combination With Peginterferon Lambda-1a and Ribavirin (RBV) in Patients With Chronic Hepatitis C Genotype 1b Who Are Treatment naive or Prior Relapsers to Alfa/RBV TherapyHepatitis CJPRN-jRCT2080222042Bristol-Myers K.K.450